<DOC>
	<DOCNO>NCT02279342</DOCNO>
	<brief_summary>The purpose study investigate effect febuxostat coronary plaque volume patient chronic stable angina hyperuricemia .</brief_summary>
	<brief_title>Effect Febuxostat Coronary Plaque Volume Patients With Chronic Stable Angina Hyperuricemia</brief_title>
	<detailed_description>Patients stable angina hyperuricemia undergo percutaneous coronary intervention ( PCI ) intravascular ultrasound ( IVUS ) enrol . Participants randomly assign one two treatment group . Febuxostat group A lifestyle modification group . At 8-12 month , routine follow angiography IVUS interrogation well endothelial function several bio marker assess .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Angina , Stable</mesh_term>
	<mesh_term>Hyperuricemia</mesh_term>
	<mesh_term>Febuxostat</mesh_term>
	<criteria>1 . Patients 20 year age old enrollment able visit 2 . Patients chronic stable angina severe coronary stenosis wich require PCI . 3 . Patients least one coronary plaque ( ≧ 500μm thickness % plaque 20 % ) nonculprit vessel . 4 . Patients hyperuricemia , serum uric acid level ＞7.0mg/dL within 2 month prior enrollement . 5 . Patients personally give write informed consent participate study . 1 . Patients undergone previous PCI lesion investigation . 2 . Patients gouty tophus , patient subjective symptom gouty arthritis within 1 year prior enrollment . 3 . Patients previous history hypersensitivity febuxostat allopurinol . 4 . Patients serious kidney disease , Acute kidney disease , nephrotic syndrome , dialysis patient , kidney transplant patient , eGFR ＜ 30 mL/min/1.73m2 , etc . 5 . Patients aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) 2 time upper limit normal . 6 . Patients follow medication enrollment Mercaptopurine hydrate , azathioprine , vidarabine , didanosine . 7 . Patients receive follow medication treatment hyperuricemia within 1 month prior enrollment Allopurinol , benzbromarone , probenecid , bucolome , topiroxostat , febuxostat . 8 . Patients otherwise judge principal subinvestigator unsuitable study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Coronary artery disease</keyword>
	<keyword>hyperuricemia</keyword>
	<keyword>coronary plaque volume</keyword>
	<keyword>IVUS</keyword>
</DOC>